Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226666 · ClinicalTrials.gov registry record
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
A clinical trial of Liver Tumor, sponsored by University of Michigan.
- Completed
- Registry status
- 107
- Enrollment target
- 1
- Study location
NCT02226666 is a study of Liver Tumor that has completed, run by University of Michigan. The registered enrollment target is 107 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02226666, a study of Liver Tumor, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
Conditions Studied
Interventions
- DRUG MRI with Multihance
- DRUG MRI with Eovist
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226666
The ClinicalTrials.gov registry entry for NCT02226666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Tumor appearing as the primary indexed condition, and to 2 interventions - of which MRI with Multihance is the first listed.
NCT02226666 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02226666 about?
NCT02226666 is a clinical study titled "Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration". The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
What is the current status of trial NCT02226666?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2013-08. Estimated completion is 2015-12.
What conditions does trial NCT02226666 study?
This clinical trial studies the following conditions: Liver Tumor.
What interventions are being tested in trial NCT02226666?
The interventions under investigation include: MRI with Multihance (DRUG), MRI with Eovist (DRUG).
Who is sponsoring clinical trial NCT02226666?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02226666 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.